Novo Nordisk A/S (NYSE:NVO) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $57.93 and last traded at $57.89, with a volume of 37638 shares trading hands. The stock had previously closed at $57.64.
A number of analysts have recently weighed in on the company. Pareto Securities upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Monday, August 5th. Jefferies Financial Group cut Novo Nordisk A/S from a “hold” rating to an “underperform” rating in a research report on Friday, August 30th. Citigroup upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 17th. ValuEngine upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Finally, Bank of America increased their price target on Novo Nordisk A/S from $355.00 to $400.00 and gave the stock a “neutral” rating in a research report on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and six have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $159.65.
The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.06. The business has a 50-day moving average price of $53.63 and a two-hundred day moving average price of $50.83. The firm has a market capitalization of $135.82 billion, a price-to-earnings ratio of 22.97, a PEG ratio of 2.30 and a beta of 0.61.
Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Friday, November 1st. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.02. Novo Nordisk A/S had a return on equity of 75.48% and a net margin of 32.44%. The business had revenue of $4.51 billion for the quarter, compared to analysts’ expectations of $4.55 billion. On average, equities research analysts predict that Novo Nordisk A/S will post 2.45 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the stock. Advisors Preferred LLC bought a new position in Novo Nordisk A/S in the 2nd quarter worth approximately $26,000. Prime Capital Investment Advisors LLC bought a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Winthrop Partners WNY LLC bought a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Valeo Financial Advisors LLC grew its holdings in Novo Nordisk A/S by 510.7% in the 2nd quarter. Valeo Financial Advisors LLC now owns 629 shares of the company’s stock worth $32,000 after buying an additional 526 shares in the last quarter. Finally, Wealthcare Advisory Partners LLC grew its holdings in Novo Nordisk A/S by 75.6% in the 2nd quarter. Wealthcare Advisory Partners LLC now owns 864 shares of the company’s stock worth $44,000 after buying an additional 372 shares in the last quarter. 7.35% of the stock is owned by institutional investors and hedge funds.
About Novo Nordisk A/S (NYSE:NVO)
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
Read More: What is the market perform rating?
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.